Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP) by Panitsas, Fotios P & Mouzaki, Athanasia
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Blood Disorders
Open Access Case report
Effect of splenectomy on type-1/type-2 cytokine gene expression in 
a patient with adult idiopathic thrombocytopenic purpura (ITP)
Fotios P Panitsas and Athanasia Mouzaki*
Address: Hematology & Transfusion Medicine, Medical School, University of Patras, Patras, Greece
Email: Fotios P Panitsas - fpanits@panafonet.gr; Athanasia Mouzaki* - mouzaki@med.upatras.gr
* Corresponding author    
Abstract
Background: In view of clinical observations and laboratory results that support a central role of
the spleen in idiopathic thrombocytopenic purpura (ITP) pathophysiology, we studied the effect of
splenectomy on type-1 and type-2 cytokine gene expression in an adult ITP case, refractory to
conservative treatment.
Case presentation: The patient was subjected to splenectomy 9 months after the diagnosis with
complete response, attaining platelet counts over 150 × 106/L within 10 days after the operation.
Two consecutive blood samples were obtained from the patient, 3 and 7 months after the
splenectomy for the purposes of this study. A control group consisted of 11 healthy adults.
Peripheral blood mononuclear cells were prepared from each blood sample and cultured in vitro
for 8 h with the addition of the mitogens phorbol myristate acetate and ionomycin. Total cellular
RNA extracted from 106 cells was submitted to semiquantitave reverse transcriptase-polymerase
chain reaction (RT-PCR) for the amplification of IL-2, IFN-γ, IL-4, IL-5, and IL-10 metagraphs. The
PCR products were run on ethidium-stained agarose gels, photographed and quantified by
densitometry.
A steep decrease of type-1 cytokine expression (IL-2, IFN-γ) and their calculated sum expressing
Th1 activity was observed at 7 months post-splenectomy compared to 3 months post-
splenectomy, in parallel with a rise of platelet count from 190 × 106/L to 265 × 106/L. The change
of type-2 cytokine expression (IL-4, IL-5, IL-10) was slight and the Th2 activity (IL-4+IL-5) remained
largely unchanged. The Th1/Th2 ratio, that reflects the pathogenic disease-specific T-cell immune
deviation, was accordingly reduced 7 months post-splenectomy (Th1/Th2 = 1.3) compared to 3
months (Th1/Th2 = 3.5).
Conclusions: The reduction of the Th1/Th2 cytokine ratio that was observed over time after
splenectomy was accompanied by full clinical remission. Nevertheless, the persistence of a type-1
polarization, even after several months following spleen removal, is suggestive of a more basic
abnormality of the immune function in these patients.
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Background
Adult autoimmune thrombocytopenic purpura (ITP) is a
chronic acquired organ-specific autoimmune thrombocy-
topenic syndrome [1]. The low peripheral platelet concen-
tration observed in ITP is the result of reduced platelet life
span because of their early removal from the peripheral
blood by the activated reticuloendothelial system of the
spleen, liver or bone marrow, after their sensitization by
autoantibodies that recognize their surface glycoprotein
antigens [2]. Apart from phagocytosis, destruction mech-
anisms include complement activation [3] and direct cel-
lular attack by T lymphocytes [4]. Ineffective
thrombocytopoiesis because of autoimmune attack of
megakaryocytes in the bone marrow contributes to the
thrombocytopenia with varying degrees among cases [2].
The production of platelet autoantibodies by B-cells is
driven by activated platelet-specific autoreactive T-cells
[5]. The phenotype of the disease-specific T helper cells
has been shown to be skewed towards type 1 cytokine
production [6-8].
The spleen is considered to be the primary site of the
autoimmune response where initiation, maintenance and
regulation of the autoimmune attack take place. The
spleen is the site of autoreactive T- and B-cell interaction
and activation, and autoreactive anti-platelet antibody
production [9]. Platelet destruction is also sited mainly in
the spleen in most patients [2,10,11].
Splenectomy is followed by reduction of autoantibody
peripheral blood titre [12,13]. Spleen cells isolated from
ITP patients produce antiplatelet immunoglobulin in in
vitro cultures [14]. The percentage of T- and B-cells with
activated phenotype is far greater in the spleen than in the
peripheral blood of ITP patients [9]. The number of circu-
lating autoreactive anti-platelet T- and B-cells declines
after splenectomy that leads to clinical remission, whereas
the peripheral blood concentration of CD3+CD4+,
CD3+CD8+, CD3+HLADR+, and CD3+CD25+  cells
increases significantly in ITP patients refractory to splenec-
tomy [15]. Changes in the histology of the spleen have
been observed in ITP patients and include follicular
hyperplasia, foam macrophages, and extramedullary
hematopoiesis, among others [16].
Splenectomy is the most clinically effective therapeutic
intervention in ITP patients, resulting in complete remis-
sion in two thirds of the patients with more than 60%
maintaining the therapeutic effect in the long term
[17,18]. Irrespective of clinical response, splenectomy
seems to affect the natural history of the disease and to
enhance the response of ITP patients to other treatments
that follow [19].
Given the important immunoregulatory role of the
spleen, we looked at the effects of splenectomy on
immune activation and immune deviation indices in the
peripheral blood of an ITP patient after splenectomy in
association with peripheral platelet counts.
Case presentation
A 42 year old woman presented in October 1999 in Patras
University Hospital (PUH) with lower limb purpura and
low platelet count (7 × 106/L). Following clinical exclu-
sion of causes of secondary thrombocytopenia [20] the
diagnosis of ITP was reached.
The patient initially received glucocorticoid treatment to
which she showed a temporary response until 6 months
later when she relapsed. She was subsequently started on
danazol without any clinical benefit. Intravenous
immune globulin administration also proved ineffective
after two 5-day cycles. As a result, the patient was sub-
jected to splenectomy 9 months after the diagnosis with
complete response, attaining platelet counts over 150 ×
106/L within 10 days after the operation. Five years later,
she remains in clinical remission.
Two consecutive blood samples were obtained from the
patient, 3 and 7 months after splenectomy for the pur-
poses of this study. A control group consisted of 11 adult
healthy volunteers (6 women and 5 men, median age 40
years, range 18–65 years). Informed consent was obtained
from the patient. PUH abides by the Helsinki declaration
on ethical principles for medical research involving
human subjects.
Peripheral blood mononuclear cells (PBMC) were pre-
pared from each blood sample by centrifugation over a
Ficoll-Paque gradient (Pharmacia, Sweden). The cells
were cultured in vitro for 8 h with the addition of 20 ng/
ml phorbol myristate acetate (PMA) and 1 µM ionomycin
(Sigma, St-Louis, MI).
Total cellular RNA extracted from 106 cells was submitted
to semiquantitative RT-PCR for the amplification of IL-2,
IFN-γ, IL-4, IL-5, and IL-10 metagraphs [8]. Primers and
conditions for the RT-PCR are summarized in Table 1. The
PCR products were run on ethidium-stained agarose gels,
photographed and quantified [8].
A sharp decrease in the expression of the type-1 cytokines
IL-2 and IFN-γ and their calculated sum expressing Th1
activity was observed at 7 months after splenectomy com-
pared to 3 months after splenectomy (Figure 1); this was
accompanied by a parallel rise of platelet count from 190
× 106/L to 265 × 106/L. Regarding type-2 cytokine gene
expression, IL-4 increased, IL-5 decreased, and IL-10
remained unchanged, whereas the change in Th2 activityBMC Blood Disorders 2004, 4:4 http://www.biomedcentral.com/1471-2326/4/4
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(IL-4 units plus IL-5 units) was slight (Figure 1). The Th1/
Th2 ratio {(IL-2+IFNγ)/(IL-4+IL-5)}, that reflects
immune deviation, was accordingly greatly reduced 7
months post-splenectomy (Th1/Th2 = 1.3) compared to 3
months (Th1/Th2 = 3.5) (Figure 2). Mean Th1/Th2 ratio
of the controls was 0.5 with 95% confidence intervals of
the mean (0.15–0.85). The Th1/Th2 values at 3 months
and at 7 months post-splenectomy lie at 6.25 and 1.6
standard deviations above the mean of the controls,
respectively.
The above results show that in this patient type-1 polari-
zation persists after removal of the spleen and attainment
of clinical remission. This may mean that the spleen is not
exclusively responsible for the coordination or the main-
tenance of the pathological immune response in this
patient, provided that no accessory splenic tissue exists.
Other disease centres may control the autoimmune reac-
tion as well, such as the liver or the bone marrow. Alterna-
tively, it is possible that ITP is the manifestation of a
general immune system malfunction that pre-existed
before the development of thrombocytopenia and persists
after removal of what seems to be the effector of a mani-
festation of an autoimmune proclivity.
Unfortunately, a pre-splenectomy sample was not availa-
ble for analysis. As a result, no conclusions can be drawn
about the effect of splenectomy on the direction of change
of Th1 activity. Based on phenotypic studies showing
increased presence of T lymphocytes with activated phe-
notype after splenectomy in ITP patients [15], it is plausi-
ble that peripheral Th1 activity may have increased after
splenectomy.
The clinical remission may be due to the removal of a
major platelet destruction site, although the underlying
immune activity that drives the destruction may remain
unaffected. Complete remission does not mean that
increased platelet destruction has stopped after splenec-
tomy. Platelet life span may still be shortened in this
patient and/or her normal platelet count may be even
higher than what was achieved after splenectomy.
The pathological immune activity seems to decrease over
time after splenectomy, as reflected by the lower Th1/Th2
ratio that is indicative of the degree of immune polariza-
tion. This may be explained by reduced stimulation of the
immune system by activated spleen reticuloendothelial
cells that present platelet antigens to T helper lym-
phocytes. In this way, it may be hypothesized that
removal of one vital component of the self-attacking
immune process can break the vicious circle that culmi-
nates in even greater immune activation, polarization,
and platelet destruction. Removal of a major site of
autoimmune activity may have abrogated recruitment of
naïve T-cells. As a result, overall autoimmune activity
wears off, as existing activated Th1 effector cells perish
leaving behind a much smaller population of peripheral
memory cells that retain the initial Th phenotype.
Another consideration that stems from the results of this
case study is that immune polarization and immune
deviation of the pathological response depend more on
upregulation of type-1 mediators rather than on suppres-
sion of type-2 cytokines, or that type-2 response is inade-
quate to control excess type-1 response in active disease.
Conclusions
Clinical improvement after splenectomy is associated
with reduced but not normalized immune activation and
polarization in the patient studied. However, the spleen
Table 1: Primers and conditions for the RT-PCR experiments performed in this study.
Gene Sequence (5'→3') T (°C) Product (bp)
IL-2 GCAACTCCTGTCTTGCATTG
AATGTGAGCATCCTGGTGAG
59 173
IFN-γ AGCTCTGCATCGTTTTGGGTTC
CAAATATTGCAGGCAGGACAACC
64 492
IL-4 CTGTGCTCCGGCAGTTCTAC
ACGTACTCTGGTTGGCTTCC
58 176
IL-5 GCTTCTGCATTTGAGTTTGCTAGCT
TGGCCGTCAATGTATTTCTTTATTAAG
59 291
IL-10 ACCCAGTCTGAGAACAGCTGC
GTTCACATGCGCCTTGATGTCT
61 260
β2m CCCCCACTGAAAAAGATGAG
TCACTCAATCCAAATGCGGC
56 150BMC Blood Disorders 2004, 4:4 http://www.biomedcentral.com/1471-2326/4/4
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seems not to be absolutely necessary for the maintenance
of the autoimmune reactivity.
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